Status:

UNKNOWN

Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction.

Lead Sponsor:

Flinders University

Collaborating Sponsors:

South Australian Health and Medical Research Institute

Conditions:

Heart Failure

Left Ventricular Systolic Dysfunction

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Contemporary heart failure (HF) guidelines recommend insertion of a primary prevention implantable defibrillator (ICD) in patients with left ventricular ejection fraction less than 35% (LVEF \< 35%) o...

Eligibility Criteria

Inclusion

  • Age equal or greater than 18 years
  • Patients with coronary artery disease (CAD) or dilated cardiomyopathy (DCM) of the idiopathic, chronic post myocarditis or familial type.
  • Left ventricular systolic impairment as defined by left ventricular ejection fraction 36-50% by any current standard technique (echocardiogram, multiple gated acquisition scan (MUGA), angiography or CMR taken in the last six months. If a LGE CMR has been taken within 2 months this scan can be used for inclusion
  • Able and willing to comply with all pre-, post- and follow-up testing, and requirements
  • On maximum tolerated doses of ACE inhibitors (or Angiotensin and Receptor Blockers if intolerant of ACE) and Beta Blockers

Exclusion

  • History of cardiac arrest or spontaneous or inducible sustained ventricular tachycardia or ventricular fibrillation unless within 48 hours of an acute MI
  • Cardiomyopathy related to sarcoidosis
  • Standard Cardiac Magnetic Resonance imaging contraindications (e.g. severe claustrophobia)
  • Currently implanted permanent pacemaker and/or pacemaker/ICD lead
  • Clinical indication for ICD or Pacemaker or cardiac resynchronisation therapy.
  • CMR LVEF ≤35% or\>50%
  • Severe renal insufficiency (eGFR\< 30mls/min/1.73m2)
  • Recent Myocardial Infarction (MI) (\<40 days) or cardiac revascularization (\<90 days)
  • New York Heart Association HF functional class IV at baseline
  • Conditions associated with life expectancy \<1 year
  • Pregnancy or in females of child-bearing potential, the non-use of accepted forms of contraception

Key Trial Info

Start Date :

July 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2025

Estimated Enrollment :

449 Patients enrolled

Trial Details

Trial ID

NCT01918215

Start Date

July 1 2015

End Date

August 1 2025

Last Update

March 7 2023

Active Locations (18)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (18 locations)

1

John Hunter Hospital

New Lambton, New South Wales, Australia, 2305

2

Princess Alexandra Hospital

Brisbane, Queensland, Australia, 4102

3

Royal Brisbane & Women's Hospital

Herston, Queensland, Australia, 4029

4

Flinders Medical Centre

Bedford Park, South Australia, Australia, 5042